

Special Issue

Improving HPV Vaccination Coverage: Current Challenges, Emerging Strategies and Future Directions: 2nd Edition

Message from the Guest Editor

In recent years, major scientific and policy developments have reshaped HPV vaccination. Modeling studies and real-world evidence have shown promising results for single-dose HPV vaccination schedules, while revised recommendations regarding age at vaccination and gender-neutral strategies are increasingly being considered and implemented. This Second Edition of the Special Issue invites high-quality original research, systematic reviews, brief reports, and policy analyses that advance our understanding of the following:

- Determinants of HPV vaccine acceptance, hesitancy, and uptake in diverse populations;
- Programmatic and implementation strategies that increase coverage and equity;
- Impact of COVID-19 and other public health disruptions on HPV vaccination programs, including the effectiveness of catch-up and school-based re-launch strategies;
- Innovative communication and education interventions to strengthen public trust in vaccination;
- Health system, policy, and economic evaluations supporting sustainable HPV vaccine delivery;
- Advances in vaccine schedules and the use of new tools such as digital reminders and novel delivery platforms to improve accessibility.

Guest Editor

Dr. Irena Ilic

Faculty of Medicine, University of Belgrade, Belgrade, Serbia

Deadline for manuscript submissions

28 February 2027



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/278571

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).